1240567-18-3

Basic information

• Product Name: 1-cyclopropyl-1H-pyrazol-4-amine
• Synonyms: 1-cyclopropyl-1H-pyrazol-4-amine;1-Cyclopropyl-1H-pyrazol-4-amine hydrochloride;1H-Pyrazol-4-amine, 1-cyclopropyl-;1-cyclopropyl-1H-pyrazol-4-amine(WXC08615)
• CAS NO: 1240567-18-3
• Molecular Formula: C₆H₉N₃
• Molecular Weight: 123.15576
• Mol File: 1240567-18-3.mol

Chemical Properties

• Boiling Point: 291.8±13.0 °C(Predicted)
• Appearance: /
• Density: 1.46±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 4.75±0.12(Predicted)
• CAS DataBase Reference: 1-cyclopropyl-1H-pyrazol-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-cyclopropyl-1H-pyrazol-4-amine(1240567-18-3)
• EPA Substance Registry System: 1-cyclopropyl-1H-pyrazol-4-amine(1240567-18-3)

Safety Data

• Hazardous Substances Data: 1240567-18-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-cyclopropyl-1H-pyrazol-4-amine is used as a building block for the synthesis of various pharmaceutical compounds for [application reason]. Its unique structure allows for the development of new drugs with specific therapeutic properties.
Used in Medicinal Chemistry Research:
1-cyclopropyl-1H-pyrazol-4-amine is used as a research tool in medicinal chemistry for [application reason]. It helps scientists understand the interactions between this compound and biological targets, leading to the discovery of novel therapeutic agents.
Used in Drug Development:
1-cyclopropyl-1H-pyrazol-4-amine is used as a precursor in the development of new drugs for [application reason]. Its cyclopropyl and amino groups can be modified to create derivatives with improved pharmacological properties, such as increased potency, selectivity, and bioavailability.
Note: The specific application reasons for each use case are not provided in the materials. You may need to fill in the details based on the actual applications and benefits of 1-cyclopropyl-1H-pyrazol-4-amine in the respective industries.

Upstream product

• 1240568-16-4 1‐cyclopropyl‐4‐nitro‐1H‐pyrazole 

Downstream Products

• 1361941-15-2 5-tert-butyl-2-(3-(5-(1-cyclopropyl-1H-pyrazol-3-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(hydroxymethyl)phenyl)isoindolin-1-one 

Relevant articles and documents

FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF

The present disclosure relates to a class of fused pyrimidine compounds of Formula I, their stereoisomers, tautomers, pharmaceutically acceptable salts, polymorphs, solvates, and hydrates thereof. The present disclosure also relates to a process of preparation of these fused pyrimidine compounds, and to pharmaceutical compositions containing them.

BENZAMIDES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF

Provided is a novel class of orally and/or topically available, selective and potent JAK inhibitors as safe and effective therapeutics against various diseases and disorders. More particularly, provided are pharmaceutical composition of these compounds and methods of their preparation and use thereof.

INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS

The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring C, X1, X2, L1, R1, R2, R3, R4, R5, R6, R7, m and n are as defined herein, which are useful as MAP4K1 inhibitors, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment or prevention of various diseases, conditions and/or disorders mediated by MAP4K1.

SULFONYLUREA DERIVATIVES AND USES THEREOF

The present disclosure relates to compounds of Formula (I) and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS

The present disclosure relates to compounds of Formula (I): (I) and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

2-substituted parazoleamino-4-substituted amino-5-pyrimidine formamide compound, composition and application thereof

The invention relates to a series of new compounds as a JAK inhibitor, as well as compositions and applications thereof, and particularly provides a series of compounds (I) that have a strong JAK inhibiting activity, or stereisomers, geometrical isomers, tautomers, pharmaceutically acceptable salts, prodrugs, metabolites, isotope derivatives, and solvates, as well as medicine compositions comprising such compounds. The invention also discloses applications of the compounds or the medicine compositions in preparation of a medicine, which is used for treatment of autoimmune diseases or cancer.

Design and synthesis of novel pyrimidine analogs as highly selective, non-covalent BTK inhibitors

BTK is a promising target for the treatment of multiple diseases such as B cell malignances, asthma, and rheumatoid arthritis. Here, we report the discovery of a series of novel pyrimidine analogs as potent, highly selective, non-covalent inhibitors of BTK. Compound 25d demonstrated higher affinity to an unactivated conformation of BTK that resulted in an excellent kinase selectivity. Compound 25d showed a good oral bioavailability in mice, and significantly inhibits the PCA reaction in mice.

PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF

Pyridone and pyrazinone compounds of Formula (I) including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.